Member Info for technick

https://www.nature.com/articles/nrd.2017.243

for anyone interested on the vaccine...

A lot more to come as more data vaccine becomes available, particularly around side effects such as immune enhancement; auto-reactive antibodies and autoimmune problems are not insignificant concerns with these types of vaccines and previous attempts to create a coronavirus vaccine have failed in large part because of these....

If you extract RNA from a sample you get a certain number of copies per ul of extracted sample. This is determined by how much virus is in the sample. 5ul will have 5x fewer copies than 25ul. A larger amount of sample transferred to the test will always give a better performance down at the LOD.

Say a test has an LOD of 10 copies and my extraction has 1 copy per ul. The 5ul reaction would have 5 copies, below the LOD and will not give a positive result. A 25ul reaction will have 25 copies, 2.5x the test LOD and will give a positive result. It’s about having copies in your sample.

Reducing the test volume reduces your test performance at the LOD of the test...

But as I said, sometimes that’s fine if you want to pass low copy numbers as negative results...

Beckman have a very large footprint, I'd be surprised if it wasn't them. They'll have to go with a vender that can guarantee continuity of supply...

My use of the word sensitivity was ambiguous. If you have 20ul of a sample going into a 96-well test which has a 4x higher volume than 384-well test which is only 5ul, then you are putting in 25% of the sample you would have when using a 384 well plate compared to a 96 well plate. This has a 75% impact on the limit of detection per ml of sample. It's the LOD that drops, but there may be political reasons why you'd want to do this, it will mean low level infections aren't picked up and reported.

It is. With infectious disease diagnostics you want to maximise your sensitivity, reducing the volume of the test by 4x is never a clever thing to do in this scenario...

We are not involved. DB said as much in his presentation because the Lighthouse labs are focusing of 384 well plates as a means to get their numbers up - forget abut the 75% drop in sensitivity that results! Bad move, no infectious disease diagnostics are done in that low volume because of sensitivity issues but hey ho.

curries favour, was that an Indian Freudian?

71 million world wide of course...

... and an estimated 71 million people have chronic hepatitis C virus infection (WHO) - again, why isn't this product being used in the UK? Wake up Government...

This RNS demonstrates how well the platform works at POC, it shouldn’t be underestimated. There are no other rapid true POC PCR devices out there. The closest competition is Cepheid, but their device isn’t portable or POC, it needs a lab to support it, GDR doesn’t. Hopefully the market will wake up to this. The world needs POC diagnostics.... both HCV and AIHL are proving that GDR can lead the way!

Not sure it’s our test, I do know the optigene test wasn’t performing well so that does suggest there is an opportunity

GDR have a lamp test too, and a PCR, both on their POC platform, outstanding

Agree Allah, I'm not convinced the UK is where they should head. Many countries that don't have infrastructure will not have access to the new mRNA vaccines and will need a room temperature stable test to continue testing their populations. This is where GDR are focused and I suspect will roll out once FDA or Indian approvals land.

My mistake, I thought I read somewhere it was a continuation of the march 20 £20Bn program, apologies

I agree flying, now that it exists they have to use it once it has FDA. I wasn't sure if they have yet applied for FDA though, I need to re-run the presentation. In any event, I think Dave underestimates the world market if this becomes a standard of care for triaging antibiotic use in infants

it's a continuation I think 'Allah'

"In the US, the total lifetime cost to society for a child with prelingual onset of profound deafness has been estimated to exceed $1m."

Approximately 90,000 babies per year in the UK are treated with gentamicin on intensive care units. UK market therefore about £3m at £35 per test. Other countries like Spain have higher mutation frequency. I think Dave said yesterday world market is about £30m per annum. A nice market for us!

Some reading for those interested...

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034737/

from https://www.ft.com/content/07f76b06-73db-4647-97b6-ef0a9a58626d

"One tender worth £22bn, released by Public Health England last week, is open to companies that make different testing equipment, including medical devices and “a range of clinical laboratory diagnostic testing services”.

Suggests we must be either under the BC or Sysmex tender as it looks to be the same one...